Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Down 15.9% in February

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 44,400 shares, a drop of 15.9% from the January 31st total of 52,800 shares. Based on an average trading volume of 3,390,000 shares, the days-to-cover ratio is currently 0.0 days.

Quoin Pharmaceuticals Stock Down 4.9 %

Shares of Quoin Pharmaceuticals stock traded down $0.02 on Thursday, hitting $0.31. 281,793 shares of the company’s stock traded hands, compared to its average volume of 2,278,447. Quoin Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $1.58. The stock has a market cap of $1.56 million, a P/E ratio of -0.08 and a beta of 1.72. The firm’s 50-day moving average is $0.44 and its 200 day moving average is $0.57.

Insider Buying and Selling at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, Director Anthony James Culverwell bought 100,000 shares of the stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $0.45 per share, for a total transaction of $45,000.00. Following the completion of the purchase, the director now directly owns 100,317 shares of the company’s stock, valued at approximately $45,142.65. The trade was a 31,545.74 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Gordon Dunn bought 122,221 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were acquired at an average cost of $0.45 per share, for a total transaction of $54,999.45. Following the completion of the transaction, the chief financial officer now owns 151,077 shares of the company’s stock, valued at approximately $67,984.65. The trade was a 423.55 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 777,777 shares of company stock valued at $350,000 over the last 90 days. 3.70% of the stock is owned by corporate insiders.

Institutional Trading of Quoin Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in QNRX. Apollon Wealth Management LLC bought a new stake in shares of Quoin Pharmaceuticals in the 4th quarter worth about $52,000. Boothbay Fund Management LLC bought a new stake in Quoin Pharmaceuticals in the fourth quarter valued at about $53,000. Renaissance Technologies LLC raised its stake in Quoin Pharmaceuticals by 244.1% during the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after buying an additional 94,431 shares in the last quarter. Finally, Altium Capital Management LLC bought a new position in Quoin Pharmaceuticals during the 4th quarter worth approximately $184,000. 8.63% of the stock is owned by institutional investors and hedge funds.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.